RecruitingNot Applicable

Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations

France300 participantsStarted 2018-11-20

Plain-language summary

The cerebral arteriovenous malformations correspond to the formation of an entanglement of morphologically abnormal vessels called nidus, which shunt the blood circulation directly from the arterial circulation to the venous circulation. The cerebral arteriovenous malformations are an important cause of hemorrhagic stroke. The hypothesis is that cerebral haemorrhage associated with a cerebral arteriovenous malformations would come from peri-nidal micro-vessels, in connection with infiltration of leucocytes and / or defective maintenance of microvascular integrity by platelets.

Who can participate

Age range

0 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient over 18 years old * Patient with a cerebral AVM for which an intervention (endovascular treatment or surgery) or only clinical monitoring * Express consent to participate in the study And * children * Free informed and express consent of both holders of the minor patient's parental authority, or, by way of derogation and only if the other holder of parental authority cannot give his or her consent within a time limit compatible with the methodological requirements specific to the conduct of the research with regard to its purposes, of one of the two holders of parental authority Exclusion Criteria: * Patient benefiting from a legal protection measure * Pregnant or breast feeding woman

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Associaton between dosage of endothelial marker and the arteriovenous malformation pronostic

Timeframe: 6 months

Associaton between dosage of platelet and the arteriovenous malformation pronostic

Timeframe: 6 months

Associaton between dosage of neutrophilic and the arteriovenous malformation pronostic

Timeframe: 6 months

Associaton between neo-angiogenesis activation markers and the arteriovenous malformation pronostic

Timeframe: 6 months

Trial details

NCT IDNCT03676868

SponsorFondation Ophtalmologique Adolphe de Rothschild

Sponsor typeNETWORK

Study typeOBSERVATIONAL

Primary completion2028-11-19

Contact for this trial

Amélie Yavchitz

01 48 63 64 54 ayavchitz@for.paris

View on ClinicalTrials.gov More Cerebral Arteriovenous Malformations trials

Plain-language summary

Who can participate

Age range

0 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Associaton between dosage of endothelial marker and the arteriovenous malformation pronostic

Timeframe: 6 months

Associaton between dosage of platelet and the arteriovenous malformation pronostic

Timeframe: 6 months

Associaton between dosage of neutrophilic and the arteriovenous malformation pronostic

Timeframe: 6 months

Associaton between neo-angiogenesis activation markers and the arteriovenous malformation pronostic

Timeframe: 6 months